Phase I/II study of Gefitnib monotherapy as neo-adjuvant chemotherapy for cN2 lung adenocarcinoma with the EGFR mutation.
Phase of Trial: Phase I/II
Latest Information Update: 12 May 2016
At a glance
- Drugs Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Pharmacogenomic
- 20 Apr 2012 Status changed from recruiting to discontinued as reported by University Hospital Medical Information Network - Japan.
- 01 Jan 2011 New trial record